Lineage Cell Therapeutics: OpRegen Makes It A Viable Speculative Buy
Source: SeekingAlpha
2025-11-13 04:10:31 ET
...
Read the full article on Seeking Alpha
For further details see:
Lineage Cell Therapeutics: OpRegen Makes It A Viable Speculative Buy
Lineage Cell Therapeutics, Inc.
NASDAQ: LCTX
LCTX Trading
3.57% G/L:
$1.885 Last:
1,186,755 Volume:
$1.94 Open:
LCTX Latest News
March 05, 2026 04:01:00 pm
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026 08:00:00 am
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
January 29, 2026 01:31:00 pm
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
January 06, 2026 08:00:00 am
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
LCTX Stock Data
$424,954,306
168,599,757
0.11%
54
N/A
Biotechnology & Life Sciences
Healthcare
US
Carlsbad
